Orexo Restructures Organizational Framework to Enhance New Product Development

Uppsala, Sweden, has become a focal point for Orexo AB as the pharmaceutical company reshapes its organizational structure for future growth. Announced on March 6, 2026, this overhaul stems from the strategic divestment of Zubsolv® within the US market and aims to bolster the development of new products and refine existing technologies, particularly focusing on AmorphOX® technology.

The transition involves pivotal changes in the management team, designed to streamline operations and enhance product development efforts. At the center of this restructuring is Lisa Moore, who has been integral to Orexo's US leadership since May 2024. Moore will step into the role of Senior Vice President of Products and Portfolio Strategy. She will spearhead the long-term vision for product development, ensuring that future offerings align with customer demands and support overall business growth. Moore, a seasoned biopharma leader with over 25 years of experience, has held significant positions in prominent pharmaceutical companies, including Emergent and Merck. Her new responsibilities also include reporting directly to the CEO and participating in Orexo's Research and Development Day slated for March 24 in Stockholm.

Another key player, Robert DeLuca, who has served as President of Orexo US Inc. since its inception in 2013, has announced his retirement. Recognized for his critical role in building the US market and successfully bringing Zubsolv to commercial success, DeLuca's departure marks the end of an era for the company. Despite stepping down, he will continue to provide mentorship for transitional projects and offer strategic advisory support to Orexo as it undergoes significant changes.

Nikolaj Sørensen, President and CEO of Orexo, shared insights on how the restructuring aligns with the company's long-term ambitions. He articulated a clear vision for the future, one that places increased emphasis on product pipeline advancement and the potential Ugrow of AmorphOX technology, a drug delivery system aimed at enhancing medication bioavailability and stability. Sorensen expressed gratitude towards DeLuca, acknowledging his dedication and lasting impact, stating, “Bob's commitment, integrity, and influence on Orexo will be enduring.”

The restructuring is not just about personnel changes; it signifies a broader strategic pivot to ensure that the company meets unmet customer needs in an evolving pharmaceutical landscape. Maintaining expertise in commercial operations and market insights is essential as Orexo aims to develop new products that address significant health challenges, including the opioid epidemic.

As Orexo embarks on this new chapter, the upcoming months will be crucial in shaping its direction and setting the pace for innovative breakthroughs in therapeutic solutions. The company urges stakeholders to stay tuned for updates as they work diligently to navigate these opportunities and challenges.

With over three decades of experience and multiple products approved globally, Orexo's commitment to advancing healthcare is reinforced through its partnerships and developmental initiatives. Interested parties may visit Orexo's official website for further details and updates on ongoing projects and innovations. Additionally, the company is active on various social media platforms, offering insights into its operations and contributions to the medical field.

This organizational realignment reflects Orexo's dedication to fostering innovation and enhancing the effectiveness of its product portfolio. The pharmaceutical landscape is fraught with challenges, yet Orexo's strategic vision positions it well to meet the evolving needs of patients and healthcare providers alike.